NEW YORK, NY / ACCESSWIRE / September 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or the "Company") (NYSE:ENFN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Enfusion and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On or around October 21, 2021, Enfusion conducted its initial public offering ("IPO"), selling 15.32 million shares of stock priced at $17.00 per share. Then, on August 6, 2024, Enfusion issued a press release reporting its financial results for the second quarter of 2024. Among other items, Enfusion reported non-GAAP earnings per share of $0.05, missing consensus estimates by $0.01, as well as revenue of $49.5 million, missing consensus estimates by approximately $475,000.
On this news, Enfusion’s stock price fell $0.68 per share, or 7.86%, to close at $7.97 per share on August 6, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Pomerantz LLP
View the original press release on accesswire.com
COMTEX_458097463/2457/2024-09-23T23:32:54